-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 -- Sienna Biopharmaceuticals,.

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Viveve Medical (NASDAQ: VIVE ) shares were ...

Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib), in addition to exploring a wide range of financial and strategic alternatives. Sienna does not intend to initiate its planned Phase 3 trials of SNA-120 until the Company secures sufficient additional capital.

The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

The big shareholder groups in Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) have power over the company. Institutions...

Available for nearly 25 years, laser hair removal is one of the most commonly performed aesthetic procedures in the world. With more than 12 million laser hair procedures performed annually in the United States1, countless patients have benefitted from the lasting results of laser hair removal, except for those with light hair. Of the 53 million people in the United States who use laser treatments, waxing and other methods to remove unwanted hair, approximately one in three are light haired2.

Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. “We believe this decision is in the best interests of Sienna and its stakeholders,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. Sienna intends to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court for the Distict of Delaware and in accordance with the applicable provisions of the Bankruptcy Code.

Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team. Mr. Chuck Abraham has been appointed Chief Executive Officer to lead the Company's commercial strategy and execution, including the planned U.S. commercial launch of Sebacia Microparticles in the US for treatment of acne.

Companies in the news are: KRTX, EROS, CARO, SNNA

On or before December 5, 2019, the Company shall update the Panel regarding the results of the Chapter 11 auction process currently being conducted under the jurisdiction of the United States Bankruptcy Court for the District of Delaware (the “Court”). The Company shall also provide a timeline for completion of the transaction and/or delisting, or, in the alternative, details regarding the financing / reorganization.

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform.   Dova Pharmaceuticals (NASDAQ: DOVA ) shares ...

Sienna Biopharmaceuticals, Inc. (SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline (the “Bidding Procedures Order”).1 Under the Bidding Procedures Order, all bids to acquire all or substantially all of the Company’s assets, are due to Cowen and Company on or before December 2, 2019 at 5:00 p.m. Eastern Time. The Bidding Procedures Order sets forth various criteria that must be satisfied for a bid to be qualified and, among other things, sets forth procedures pursuant to which Sienna may select one or more “stalking horse bidders”.